PM Group appoints Andrew D. Skibo as non-executive director of US Board
31 October 2017
Andrew (Andy) D. Skibo
PM Group has appointed Andrew D. Skibo (Andy Skibo) as a non-executive director of the US board of PM Group, the international engineering, architecture and project management firm headquartered in Ireland.
Andy is currently head of global biologics operations and head of global engineering and global real estate for Astra Zeneca, responsible for mAb and vaccine production operations in the US, UK and Europe, as well as global engineering operations.
Andy Skibo has served as chair and board member of the International Society for Pharmaceutical Engineering (ISPE). He is currently chair of the Global Pharmaceutical Manufacturers Leadership Forum (GPMLF).
He has served as Executive Vice President of Operations at MedImmune, responsible for Engineering. Andy was Vice President of Corporate Engineering & Capital Projects at Amgen Inc. He was President of the Life Sciences Group at Foster Wheeler and served in various engineering management positions at Skanska, Inc., Life Sciences International, Inc., A.D. Skibo & Associates, Inc., and Genentech, Inc.
Announcing the appointment, PM Group CEO Dave Murphy said: “Andy brings a substantial depth and breadth of expertise to our US Board, as we look to accelerate our growth in the US market. We have known Andy for a long time and we look forward to working with him over the coming years.”
Andy holds a MSc in Chemical Engineering with a specialty in biomedical engineering and a BSc in Chemistry, both from the Massachusetts Institute of Technology.http://www.engineersjournal.ie/2017/10/31/pm-group-appoints-andrew-d-skibo-non-executive-director-us-board/http://www.engineersjournal.ie/wp-content/uploads/2017/10/andrew-skibo-pm-group.pnghttp://www.engineersjournal.ie/wp-content/uploads/2017/10/andrew-skibo-pm-group-300x300.pngNewsPM Group